Background: D6 is an atypical chemokine receptor involved in chemokine degradation and resolution of acute infl ammatory responses in mice. Emerging evidence suggests that D6 might behave differently in human chronic infl ammatory conditions. We, therefore, investigated the involvement of D6 in the immune responses in COPD, a chronic infl ammatory condition of the lung. Methods: D6 expression was quantifi ed by immunohistochemistry in surgical resected lung specimens from 16 patients with COPD (FEV 1 , 57% Ϯ 6% predicted) and 18 control subjects with normal lung function (nine smokers and nine nonsmokers). BAL was also obtained and analyzed by fl ow cytometry, immunofl uorescence, and molecular analysis for further assessment of D6 involvement. Results: D6 expression in the lung was mainly detected in alveolar macrophages (AMs). The percentage of D6 1 AMs was markedly increased in patients with COPD as compared with both smoker and nonsmoker control subjects ( P , .0005 for both). D6 expression was detected at both transcript and protein level in AMs but not in monocyte-derived macrophages. 
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Original Research COPD C OPD is a worldwide public health problem that reduces the quality of life, increases the frequency of contact with health-care providers, causes frequent hospital admissions, and carries an increased risk of death. [1] [2] [3] Active smoking, the main risk factor for COPD development, instigates an infl ammatory response in the larger bronchi and peripheral lung of all smokers. This infl ammatory process is amplifi ed and persists long after smoking cessation in those susceptible smokers who develop COPD. [4] [5] [6] [7] [8] [9] [10] [11] [12] The mechanisms leading to the initiation and persistence of this infl ammatory immune response are not fully understood, but several studies have implicated T cells, macrophages, and neutrophils as important players in disease pathogenesis. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Leukocyte recruitment to sites of infl ammation is orchestrated by chemokines, a large family of chemotactic cytokines recognized by G protein-coupled receptors. In addition to conventional chemokine receptors able to trigger cell migration, a small family of receptors, characterized by promiscuous ligand binding and inability to promote cell migration, has been identifi ed. These atypical chemokine receptors are believed to control chemokine bioavailability, thus immune responses due to either lack of migration of dendritic cells to lymph nodes or release of myeloid suppressor cells from bone marrow. 31, 32 Furthermore, in M tuberculosis infection, D6 and the related CC chemokines are required for an appropriate immune response, which controls pathogen growth. 27 Mechanisms promoting the persistent activation of adaptive immunity, possibly with an autoimmune component, have been described in COPD, wherein the chronic infl ammation initiated by cigarette smoking may break the normal mechanisms of tolerance and promote lung damage. 10 We became interested in investigating the expression of D6 receptor in COPD, a condition in which the chronic infl ammatory process may cause variable degrees of disease severity, making this condition a potential good model to study the behavior of this receptor. To this aim, D6 expression was evaluated in the lungs of smokers with COPD as well as those of smoker and nonsmoker control subjects. Furthermore, D6 was examined at both protein and mRNA levels in alveolar macrophages (AMs) obtained from BAL and in ex vivo monocyte-derived macrophages (MDMs). Finally, possible correlations with infl ammatory cell infi ltration and markers of immune activation in peripheral lung were examined.
Materials and Methods
Subjects undergoing lung resection for solitary peripheral carcinoma or lung volume reduction surgery for severe emphysema were recruited to the study: 16 smokers with COPD and 18 asymptomatic control subjects with normal lung function (nine smokers, nine nonsmokers). COPD was defi ned according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) international guidelines. 2 The study conformed to the Declaration of Helsinki, was approved by the local institutional review board (Padova Hospital Ethical Committee for Experimentation; project number: 2144P), and informed written consent was obtained for each subject undergoing surgery.
Tissue blocks were taken from the subpleural parenchyma of the lobe obtained at surgery, avoiding areas involved by tumor. Samples were fi xed in 4% formaldehyde and, after dehydration, embedded in paraffi n as previously described. [5] [6] [7] [8] Sections 5-m m thick were cut and processed for immunohistochemical analysis of D6 expression (e-Appendix 1). D6 expression was quantifi ed in AMs within alveolar spaces and in those in contact with the alveolar walls. Moreover, we investigated potential correlations between D6 expression and other immune/infl ammatory parameters known to be upregulated in COPD (CD8 1 cells infi ltrating the alveolar walls, IL-32, tumor necrosis factor [TNF]-a , B-cell activating factor of the TNF family [BAFF] , and phospho-p38 mitogen-activated protein kinase [MAPK] ). Details are provided in e-Appendix 1. Finally, to investigate the disease specifi city, we evaluated D6 expres sion in other chronic infl ammatory lung diseases: two autoptic samples from subjects with asthma and two explanted lungs from subjects with cystic fi brosis who underwent lung transplantation.
BAL was obtained from 10 subjects with COPD and fi ve control smokers who underwent bronchoscopy for diagnostic assessment of suspect lung cancer. BAL cells were centrifuged, resuspended, frozen, and stored at 2 80°C for subsequent analyses. Immunofl uorescence analysis with confocal microscopy was participating in the appropriate resolution of infl ammatory responses and protecting from excessive tissue damage. 14, 15 Examples of these receptors include duffy antigen receptor for chemokines, chemocentryx chemokine receptor, and the decoy receptor D6, a highly promiscuous receptor capable of binding, internalizing, and rapidly degrading most of the CC infl ammatory chemokines. [16] [17] [18] [19] [20] [21] D6 is predominately localized in intracellular vesicular pool and is rapidly mobilized to the cell surface when high levels of chemokines are present to drive them to degradative compartments. 22 The majority of the current information about D6 biology comes from animal studies investigating resolution of acute infl ammatory responses. [23] [24] [25] In this context, D6 seems to have an antiinfl ammatory role, as D6-defi cient mice develop an exaggerated and prolonged response when challenged with various infl ammatory stimuli, such as Freund adjuvant, 23 phorbol esters, 25 allergens, 26 or Mycobacterium tuberculosis . 27 The few studies that investigated D6 expression in human settings reported its signifi cant upregulation in chronic infl ammatory conditions, such as systemic sclerosis, infl ammatory bowel disease, and cardiac allograft rejection. [28] [29] [30] Of interest in this context, there is emerging evidence that D6 activity is also required for mounting adaptive immune responses in certain experimental conditions. For example, in animal models of autoimmune encephalomyelitis and graft-vs-host disease, the absence of D6 results in impaired adaptive to the alveolar walls, but not in lymphatic vessels, as it has been reported before 18, 29 ( Fig 1 ) . Relating the magnitude of D6 expression to the clinical status, we found that D6 expression in macrophages within the alveolar space was signifi cantly increased in patients with COPD compared with smoker and nonsmoker control subjects. D6 expression tended to be higher in severe COPD than in mild to moderate COPD, but this difference did not reach statistical significance (e-Appendix 1). Similarly, D6 was upregulated in macrophages adjacent to the alveolar walls of smok ers who develop COPD but not in smokers who maintained normal lung function ( Fig 1 ) . Conversely, D6 expression was scarce within the alveolar walls and was not signifi cantly different among the three groups of subjects examined ( The expression of D6 was not related to potential confounding factors, such as smoking status, cumulative smoking exposure, age, sex, or presence of lung cancer (e-Appendix 1). Of interest, the evaluation of D6 expression was not observed in other infl ammatory disorders of the lung, such as asthma or cystic fi brosis, either in AMs or in other cells (e-Appendix 1).
To further evaluate the expression of D6 in macrophages, we analyzed BAL samples by fl ow cytometry, molecular analysis, and immunofl uorescence. The analysis by fl ow cytometry showed that the great majority of BAL cells were represented by alternatively activated M2 macrophages (CD45 1 /CD68 1 /CD16 1 / CD206 1 ) both in control smokers and patients with COPD ( Fig 2 ) . Molecular analysis showed that D6 mRNA levels were signifi cantly increased in BAL macrophages from patients with COPD as compared with control smokers, a fi nding that confi rms the expression of D6 observed by immunohistochemistry. Confocal microscopy confi rmed the high expression of D6 in AMs of patients with COPD ( Fig 2 ) . As previously reported in other cell types, 34 D6 expression in macrophages exhibited a cytoplasmic granular pattern with a preferential colocalization with the intracellular macrophage marker CD68 rather than with the plasma membrane mannose receptor CD206 (Pearson correlation coeffi cient, 0.66 Ϯ 0.03 and 0.33 Ϯ 0.02, respectively) ( Fig 2 ) .
The expression and function of D6 were also investigated in ex vivo systems using MDMs. At variance with the in vivo setting, D6 transcript levels were barely detectable in MDMs, either in resting conditions (M0), after innate activation using TNF-a , or after polarized activation to classic (M1) or alternative (M2) macrophages ( Fig 2 ) . These results suggest that D6 expression by AM in COPD is likely dependent on microenvironmental stimuli present in the alveolar space of patients with COPD. In support of D6 activity in AMs of patients with COPD is the analysis of performed to detect D6, CD68, and mannose-receptor (CD206). Flow cytometry analysis was performed with CD45-PerCP, CD16-PE, or CD206-FITC and analyzed by BD FACSDiva Software (Becton, Dickinson and Company). Semiquantitative evaluation of D6 mRNA level was assessed by TaqMan Gene Expression Assay (Life Technologies). In addition, these analyses were performed in MDMs differentiated ex vivo from circulating monocytes. These cells were analyzed either in basal conditions (M0), after innate activation (TNF-a 100 ng/mL; 24 h) or after polarization to classic (M1) (100 ng/mL lipopolysaccharide plus 20 ng/mL interferon-g ) or alternative (M2) (20 ng/mL IL-4) activation. 33 Finally, D6-mediated chemokine degradation was investigated, using either the D6 ligand CCL3L1 or CXCL8/IL-8, not recognized by D6 and used here as a negative control. All details are reported in e-Appendix 1.
Group data were expressed as mean and SE or as median and range. Differences between groups were analyzed using tests for multiple comparisons: the analysis of variance or Kruskall-Wallis test. Unpaired t test or Mann-Whitney U test were subsequently carried out. Spearman rank or Pearson correlation coeffi cients were used to examine the association between histologic parameters as well as those with functional data. Probability values of P , .05 were accepted as signifi cant.
Results
The clinical characteristics of the subjects are reported in Table 1 . There were no demographic differences among the three groups of subjects, and the smoking history was similar in smokers with COPD and control smokers. Among patients with COPD, eight had severe to very severe disease (GOLD stage III-IV), and eight had mild to moderate disease (GOLD stage I-II). The values of Pa o 2 were significantly reduced in smokers with COPD compared with both control groups, whereas the values of Pa co 2 were not signi fi cantly different. Smokers with mild to moderate COPD and control subjects with normal lung function did not receive antiinfl ammatory therapy (eg, oral or inhaled corticosteroids) or antibiotics within the month preceding surgery, or bronchodilators within the previous 48 h. All patients with severe to very severe COPD were treated with inhaled anticholinergic drugs and/or b 2 agonists/corticosteroids, but none with oral steroids or antibiotics.
The majority of D6 immunoreactivity was detected on AMs in the alveolar spaces and in those adjacent The correlations with expression of IL-32 and TNF-a remained signifi cant even when considering patients with COPD only ( r 5 0.67, P 5 .01; and r 5 0.73, P 5 .01, respectively). Of interest, when patients with COPD were subcategorized according to the relative expression of D6 (above or below the median value), all patients with COPD with high levels of D6 were clustered within high levels of IL-32 and TNF-a , chemokine degradation, which shows a decrease in the level of the D6-ligand CCL3L1, whereas the concentration of the non-D6 ligand CXCL8/IL-8 was not modifi ed ( Fig 2 ) . These results are suggestive of an active degradation of the CCL3L1 by D6 in AMs. To gain some insight into the mechanisms sustaining D6 selective induction on AMs in vivo, we analyzed the relationship between the expression of D6 and markers of immune activation previously reported to be increased in patients with COPD. Data for this anal ysis were available from previous studies and are reported in the e-Appendix 1. When all subjects were considered as a group, D6 expression was positively correlated with the number of CD8 1 cells infi ltrating the alveolar walls ( r 5 0.42, P 5 .02) and with markers of immune activation (IL-32: r 5 0.79, P , .0001; TNF-a : r 5 0.74, P 5 .0002; BAFF: r 5 0.55, P 5 .003; phosphop38 MAPK: r 5 0.60, P 5 .003) ( Fig 3 ) . Conversely, Figure 1 . A, B, Expression of D6 in smokers with COPD was not detected in lymphatic vessels (A), even in the subpleural regions where they are abundant as identifi ed by podoplanin immunostaining (B). C-F, By contrast, D6 expression in smokers with COPD was prominent in alveolar macrophages (AMs) both in those within the alveolar spaces (C) and in those adjacent to alveolar walls (D) and almost absent in AMs of smoker (E) and nonsmoker control subjects (F). D6 and podoplanin staining are in brown. G, H, Quantifi cation of D6 expression in AMs within the alveolar spaces and in those adjacent to the alveolar walls, respectively. In each box plot, the box bottom and top denote the 25th and 75th percentiles, respectively, the solid line is the median, and the brackets are the 10th and 90th percentiles. P values are calculated using the Kruskall-Wallis test ( P , .05 for both) followed by Mann-Whitney U test (* P , .05, ** P , .01, and *** P , .005).
TNF-a or classic (M1) or alternative (M2) activation pathways. The observation of increased D6 expression in the lungs of patients with COPD is in keeping with the few previous reports that investigated D6 in human chronic infl ammatory conditions. Indeed, these studies reported D6 upregulation in intestinal lymphatic vessels in Crohn's disease-ulcerative colitis 29 as well as in peripheral blood mononuclear cells in systemic sclerosis. 28 In contrast with previously reported localization of D6 in lymphatic vessels in mice and in some human studies, 18, 29 we found that in COPD D6 expression was predominantly, if not exclusively, detected in AMs, an observation that we confi rmed in both surgical specimens and BAL. These results are in keeping with the fi ndings of a recent study showing that D6, which was found to be upregulated in cardiac allograft whereas levels of these cytokines were much more scattered in patients with COPD with low D6 expression ( Fig 3 ) .
Discussion
The present study demonstrates an increased expression of the atypical chemokine receptor D6 in peripheral lung from smokers with COPD but not in smoking subjects who did not develop the disease and nonsmoker control subjects. The expression of D6 was almost exclusively present in AMs, as confi rmed by immunohistochemical, molecular, and confocal microscopy analysis, and was correlated with markers of immune activation. Conversely, D6 was barely expressed in ex vivo differentiated macrophages and could not be induced by either innate activation by Figure 2 . A, fl ow cytometry analysis of BAL cells in COPD (black columns) and control smokers (white columns). B, Gating strategy to identify human leukocyte population from BAL. The analysis was based on CD45 staining to defi ne total leukocytes (R1); human macrophages were identifi ed as CD16 1 /CD14 1 subpopulation (R2). Finally, CD206 relative expression was calculated in R2-gated macrophages. Doublets and dead cells were excluded prior to analysis. C, D6 mRNA expression by real time reverse transcriptase polymerase chain reaction in human choriocarcinoma BeWo cells (positive control), in human BAL samples of patients with COPD and control smokers, and in ex vivo differentiated MDMs in resting conditions (M0) or after polarized activation (M1 and M2). The amount of D6 was calculated as relative abundance of D6 expression over GAPDH. P values are calculated using the Student t test (* P , .05 and *** P , .005). D, confocal microscopy of AMs isolated from COPD and control smokers and ex vivo polarized MDMs. Cells were stained for CD68 (red), CD206 (green), and D6 (cyan). Cellular and nuclear morphology are shown by Nomarski technique (DIC) and DAPI staining (blue), respectively. E, chemokine degradation assay in BAL cells of patients with COPD. Total BAL cells were incubated with 1 nM CCL3L1 (black columns) or 1 nM CXCL8/IL-8 (white columns) at 37°C for the indicated time points. Results are indicated as 100 minus the percentage of intact chemokine, measured by enzyme-linked immunosorbent assay test. DAPI 5 fl uorochrome 49,6-diamidino-2-phenylindole; DIC 5 differential interference contrast; GAPDH 5 glyceraldehyde phosphate dehydrogenase; MDM 5 monocyte-derived macrophage; SSC 5 side scatter detector. See Figure 1 legend for expansion of other abbreviation.
an important role in this setting. Of interest, in our study, increased expression of D6 was observed in clusters of macrophages within the alveolar spaces as well as in macrophages that were in close contact with the alveolar walls. In this site, macrophages can modify the function of type 2 pneumocytes, which normally rejection, 30 was predominantly localized to graftinfi ltrating macrophages. Furthermore, in that study, the degree of D6 upregulation was related to the severity of the rejection. These fi ndings suggest that macrophages are important determinants of the fate of adaptive immune responses and that D6 may have Figure 3 . A-D, When all subjects were considered as a group, D6 expression was positively correlated with the markers of immune activation: CD8 1 cells infi ltrating the alveolar walls (A), IL-32 (B), and TNF-a (C) and negatively correlated with lung function parameters (FEV 1 /FVC) (D). E, F, When stratifi ed according to the expression of D6 (above or below the median value), patients with COPD with high D6 levels showed levels of IL-32 and TNF-a signifi cantly higher than patients with COPD with low D6 levels in which the levels of these cytokines were scattered. P values (Mann-Whitney U test): * P , .05, ** P 5 .01. TNF 5 tumor necrosis factor. membrane and the endolysosomal compartment to internalize infl ammatory cytokines, it may return loaded with antigenic peptides. All these results seem to point to the possibility that in chronic infl ammatory states, upregulation of D6, which expression might initially increase in the attempt to restrain the infl ammatory response, may eventually promote immune activation and disease progression. These possibilities would go along with the fi nding that in humans D6 has been found to be increased in diseases with a likely autoimmune component, like cardiac allograft rejection, Crohn's disease-ulcerative colitis, and COPD, but not in asthma and cystic fi brosis, in which the autoimmune component does not seem to be important.
A possible criticism of our fi ndings could be that the presence of lung cancer in most of our patients may have infl uenced our results. We were careful to examine only areas free of disease and distant from tumor, and moreover, since lung cancer was present even in smoker and nonsmoker control subjects, we believe that our fi ndings are valid. Furthermore, patients with COPD undergoing lung volume reduction surgery, who did not have lung cancer but had severe COPD, had higher levels of D6 expression than control subjects with lung cancer. Finally, although our study did not fully address the functional consequences of D6 expression in AMs, we believe these results have the potential to provide the clinical framework for proper functional investigations.
In conclusion, the atypical chemokine receptor D6 is expressed in human AMs, is upregulated in COPD, and is correlated with markers of disease severity and immune activation. These data suggest that, besides its known scavenger activity in acute infl ammation, D6 probably has additional functions in chronic infl ammatory conditions, possibly promoting immune activation.
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